Targeted Therapy and the Future of Lung Cancer Management

Lung cancer is the leading cause of cancer death among both men and women, accounting for about one-fifth of all cancer deaths. It is also the most frequently occurring cancer globally. Lung cancer is broadly split into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), with 80-85% classified as NSCLC.

AstraZeneca has a portfolio of approved and potential new medicines in late-stage clinical development for the treatment of NSCLC across all stages of disease and lines of therapy. Our approach is focused on using ground-breaking science to further our understanding of lung cancer by identifying biomarkers which provide actionable targets for the development of precision medicines. Biomarkers are biological molecules found in body fluids or tissues that provide insight into the state of the disease, such as gene mutations or protein expressions, and are integral to understanding its biology.

Ongoing studies are investigating the use of targeted agents, immunotherapies, and other combination approaches that aim to address this significant unmet need.

-----------------
Global site:
Careers site:

Follow us:
Twitter:
LinkedIn:
Instagram:
Facebook:

AstraZeneca,AZN,Pascal Soriot,MedImmune,pharma,cancer,cancer risk,lung cancer,non-small cell lung cancer,NSCLC,small cell lung cancer,SCLC,cancer cells,biomarkers,oncology,genetic mutation,lung adenocarcinoma,squamous cell carcinoma,lung cancer awareness,#LCSM,tyrosine kinases,tyrosine kinases inhibitors (TKI),Epidermal growth factor receptor (EGFR),genetic testing,genomic testing,tumour testing,tumour drivers and resistance (TDR),tumour,science,genes,